Business
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency (KDCA) and GC Biopharma, was granted regulatory approval in April as Korea's 39th locally developed new drug.
About this update from Gc Biopharma Corp.
[{"type":"text","content":"- First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility ","length":152,"tagName":"p","attribs":{}},{"type":"text","content":"YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency (KDCA) and GC Biopharma, was granted regulatory approval in April as Korea's 39th locally developed new drug.","length":425,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/GC Biopharma)","displaySize":"","headline":null,"caption":"(PRNewsfoto/GC Biopharma)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/4b834899abdf3d99fcde8560d438cc9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B0c2J77qVeMlBCJvcjoKKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4b834899abdf3d99fcde8560d438cc9a","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/1888566/GC_Biopharma_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The initial supply will be delivered to the KDCA for national stockpiling, supporting public health preparedness against biological threats, including potential bioterrorism.","length":174,"tagName":"p"},{"type":"text","content":"BARYTHRAX inj. is the first anthrax vaccine globally to be developed using recombinant protein technology. Unlike conventional vaccines that use live attenuated or avirulent strain of Bacillus anthracis, BARYTHRAX inj. is based solely on the purified Protective Antigen (PA) protein, a principal component of the anthrax toxin.","length":327,"tagName":"p"},{"type":"text","content":"Clinical studies showed that BARYTHRAX inj. induces neutralizing antibodies that meet the predefined immunogenicity thresholds. This result supports its potential to effectively protect individuals in the event of anthrax exposure.","length":231,"tagName":"p"},{"type":"text","content":"Furthermore, the safety assessment confirmed that the primary adverse events reported in the BARYTHRAX inj. group —such as injection-si...